Method of treating arterial hypertension with metabolic syndrome. RU patent 2504390.
|
Method for pore formation in hepatocyte membranes by bacillus cereus hemolysin ii processing / 2504389 Invention refers to biotechnology and represents a method involving Bacillus cereus hemolysin (HlyII) hemolysin processing of primary membrane hepatocyte and determining the membrane permeability after HlyII processing. Substance of the presented invention consists in the fact that the action of the HlyII preparation on the cell membranes provides the more effective transport of various low-molecular compounds through the cell membranes. The object in view is to form nanometric pores in the hepatocyte membranes ensured by the action of the low concentration of the purified HlyII preparations on the primary hepatocytes. An increase of the hepatocyte membrane permeability after the HlyII preparation processing is determined by microspectral analysis of low-molecular fluorescent dyes. As observed, the increased permeability of the above dyes into the hepatocyte permeability characterises higher permeability of the processed hepatocyte membranes. |
 Agent for extreme performance stimulation, method for preparing and using it / 2503459Group of inventions refers to medicine and concerns an agent for extreme performance stimulation in the form of a mixture of peptides of molecular weight 2000-5000 Da and peptides of molecular weight 500-900 Da prepared of the infant cattle and/or swine brain in ratio of the ingredients 2/1-3/1, in the concentration of the mixture of peptides in the agent of 5.0-10.0 mg/ml of the aqueous solution or 5.0-10.0 mg/g in the witepsol suppository; a method for preparing the above agent for extreme performance stimulation; using the above agent for parenteral administration or for rectal administration. |
 Agent for extreme performance stimulation / 2503457Invention refers to medicine, namely to an agent for extreme performance stimulation. The agent represents a mixture of peptides of molecular weight 2000-5000 Da prepared of the infant cattle and/or swine brain, namely of the ventral and dorsal hippocampus of cingulate sulcus (sulcus cinguli) of amygdaloid body (nucleus amygdalae) of the limbic system, as well as of caudate nucleus (nucleus caudatus) and hypothalamus in the concentration of the mixture of peptides in the agent of 5.0-10.0 mg/ml of the aqueous solution or 5.0-10.0 mg/g in the witepsol suppository. |
 Somatic cell reprogramming method / 2502799Composition contains pluripotent cells of a mammal and a pharmaceutically acceptable carrier. Besides, a generation method of reprogrammed somatic cell is disclosed. Proposed group of inventions can be used in cell therapy field. |
|
Method of body exposure / 2502528 Invention refers to medicine, more specifically to physiotherapy, otorhinolaryngology, audiology, rehabilitation medicine, and may be used for the physiotherapeutic body exposure in the diseases developed in cerebral and cervical human tissues and organs, such as perceptive hearing loss, siagonantritis, eustachitis, temporomandibular dysfunctional pain syndrome, odontogenous or rhinogenous trifacial neuralgia, Bell's palsy etc. For this purpose, a concha of auricle is exposed to electric current by introducing an electrode into an ear to contact a cavity and cup of concha tightly. Besides, the above are exposed to electric current through an electrode placed into a nasal passage. The electrodes are wrapped in a wet tissue made of a non-woven material with surface density 160-180 g/m2 containing a polymer layer of sodium alginate containing a drug preparation or a mixture thereof. The exposure is generated by direct electric current with its intensity to be gradually increased from 1 to 5 mA. The procedures are sequential at first from one side, and then from the other side. The exposure time makes 10-15 minutes from each side. The therapeutic course is 8-12 daily procedures. |
|
Method for prevention of premature human ageing / 2502517 Invention refers to medicine, namely gerontology, and may be used for preventing the premature human ageing. That is ensured by adding the food ration with min. 50 g of the functional foodstuff 'Samarskiy Zdorovyak' per one intake - with breakfast or lunch or dinner with underlying diet therapy. |
 Method of treating spasticity accompanied by improved consciousness in patients in vegetative state / 2502503Invention refers to medicine, namely to neurology, and may be used for treating spasticity accompanied by improved consciousness in the patients in the vegetative state. That is ensured by administering Xeomin (botulinumtoxinA free from complexing proteins) into the spastic muscles of all the extremities and related body segments regardless of the contractions in total dose of 400-1300 units. The dose shall not exceed 24 unit/kg of body weight in 1-3 stages. The stages follow at least every 3 days. Every 1-day stage involves administering 5-50 units in each accessible muscle or muscle group with the maximum tone in max. total dose 500 units dissolved in 12.5 unit/ml. The injections are distributed uniformly along the area without electromyography. The following courses are similar if observing spasticity and/or if clinically reasonable. The length of one course is up to 3 weeks. |
 Histone deacetylase inhibitors / 2501787Invention relates to compounds of general formula (I) , where is a substituted 5-member heteroaryl ring selected from thienyl, thiazolyl, oxazolyl, pyrrolyl, imidazolyl or pyrazolyl, W is selected from a group comprising N and -C=; M is selected from a group comprising -C(O)N(R1)OR2, -CXCONR1R2 and -C(O)OR1, or M is -C1-C2alkyl-C(O)N(R1)OR2, wherein is , R1 and R2 are independently selected from a group comprising -H, C1-C3-alkyl, C6-aryl, and C1-C3-alkyl-C6-aryl; R is selected from a group comprising H, C1-C3alkyl, halogen, NR1R2, -OR1 and C6aryl; n is an integer from 0 to 1; L and Y are as indicated in the claim; and to compounds of formula (II) , where L2 is selected from a group comprising H, - C0-C3alkyl- C6aryl, -C0-C3alkyl-heteroaryl, where the heteroaryl is pyridyl; -C1-C6alkyl, Y and M are the same as for compounds of formula (I). The invention also relates to a pharmaceutical composition based on compounds (I) and (II), having inhibiting action on histone deacetylase (HDAC), a method of inhibiting and a method of treating a disease which is sensitive to the HDAC inhibitor. |
|
Nutritional composition promoting normal development and growth / 2501553 Invention refers to pharmaceutics and represents a nutritional composition for an infant or: : a child containing lipid or fat, a protein source, a source of long-chain polysaturated fatty acids which contains docosahexaenoic acid; a supplementary calcium source to 2.5 wt % with at least 20% of the supplementary calcium source representing calcium gluconate, and PDGF-β 0.015 to 0.1 ppm (pg/mcg). |
 Agent for increasing life span and method for using it / 2501552Invention refers to biology, preferentially to medical genetics, and describes the agent for increasing life span of Drosophila melanogaster containing ammonium pyrrolidine dithiocarbamate (PDTC). The agent is orally administered in the concentration of 20 mg/l in the course of a lifetime. The agent is not gender-specific and enables increasing the life span of both male, and female Drosophila melanogaster considerably: average (improves quality of life) and maximum (delays the ageing rate). |
|
Pharmaceutical formulation for treating diseases associated with endothelial dysfunction / 2504375 Present invention refers to medicine. A pharmaceutical formulation for the treating diseases associated with endothelial dysfunction contains an active ingredient presented by a methyl pyridine derivative - 1.0-6.0 wt %; purine - 10.0-80.0 wt % and additive agents - the rest. The active substance is presented by compounds of a group: 3 -(N,N-dimethyl carbamoyloxy)-2-ethyl-6-methylpyridinium succinate, 3-methylpyridinium succinate, 2-ethyl-6-methyl-3-hydroxypyridinium hydrochloride, 6-trichloromethyl-2-chloropyridine (nitrapyrin), 2-ethyl-6-methyl-3-hydroxypyridine succinate. Purine is presented by inosine, adenosine, hypoxanthine. The pharmaceutical formulation may be presented in the form of injections, lyophilisate, solid capsules, tablets and suppositories. |
 Histamine h3 receptor antagonists / 2499795Present compounds can be used, for example, in treating diseases of the central nervous system, peripheral nervous system, cardiovascular system, pulmonary system, gastrointestinal system and the endocrine system. |
 Phenylaminopyrimidine compounds and uses thereof / 2498983Invention relates to novel phenylaminopyrimidine compounds of formula I, which are JAK kinase inhibitors. In particular, these compounds selectively act on JAK2 kinase. The compounds can be used to treat diseases such as immunological and inflammatory diseases; hyperproliferative diseases, myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases. In the compound of formula I , Q and Z are independently selected from N and CR1; R1 is independently selected from hydrogen, halogen, R2, OR2, OH, R4, OR4, CN, CF3, (CH2)nN(R2)2, where n equals 1,2 or 3, NO2, R2R4, NR2SO2R3, COR4, NR2COR3, CO2H, CO2R2, NR2COR4, R2CN, R2OH, R2OR3 and OR5R4; or two substitutes R1 together with carbon atoms with which they are bonded form an unsaturated 5- or 6-member heterocyclic ring containing 1-4 N atoms; R2 is C1-4alkyl; R4 is R2, C2-4alkenyl or phenyl; R4 is NH2, NHR2, N(R1)2, substituted or unsubstituted morpholine, CH2morpholine, substituted or unsubstituted thiomorpholine, substituted or unsubstituted thiomorpholino-1-oxide, substituted or unsubstituted thiomorpholino-1,1-dioxide, substituted or unsubstituted piperazinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted imidazolyl, substituted or tetrahydrofuranyl unsubstituted and substituted or unsubstituted tetrahydropyranyl; R5 is C2-4alkylene; R6-R9 are independently selected from H, RXCN, halogen, substituted or unsubstituted C1-4alkyl, OR1, CO2R1, N(R1)2, NO2 and CON(R1)2, wherein at least one of R6-R9 is RXCN; the rest of the values of the radicals are given in the claim. |
 Novel 1,2,3,4-tetrahydroquinoxaline derivative containing phenyl group as substitute, having sulphonic acid ester structure or sulphonic acid amide structure, and having glucocorticoid receptor binding activity / 2498980Invention relates to compounds of general formula (1) or salts thereof, where in formula (1) R1 is a lower C1-C6alkyl group, a lower C3-C6cycloalkyl group, a phenyl group, a heterocyclic group, which relates to a residue formed by removing a hydrogen atom from a saturated or unsaturated monocyclic heterocyclic ring containing one, two or three heteroatoms in the ring, selected from a nitrogen atom, an oxygen atom and a sulphur atom, or a phenyl(C1-C6alkyl) group; in cases when R1 is a lower C1-C6alkyl group, that lower C1-C6alkyl group can have, as substitute(s), one, two or three groups selected from a halogen atom, a heterocyclic group which relates to a residue formed by removing a hydrogen atom from a saturated monocyclic heterocyclic ring containing one or two heteroatoms in the ring, selected from a nitrogen atom and an oxygen atom, a carboxyl group, a lower C1-C6alkoxycarbonyl group, a lower C1-C6alkylamino group, a lower C1-C6alkylamino group, substituted with a lower C1-C6alkylamino group, a lower C1-C6alkylamino group, substituted with a phenyl group; in cases when R1 is a phenyl group, a heterocyclic group which relates to a residue formed by removing a hydrogen atom from a saturated or unsaturated monocyclic heterocyclic ring containing one, two or three heteroatoms in the ring, selected from a nitrogen atom, an oxygen atom or a sulphur atom, or a phenyl(C1-C6alkyl) group, that phenyl, heterocyclic or phenyl(C1-C6alkyl) group can contain, as substitute(s), one, two or three groups selected from a halogen atom, a lower C1-C6alkyl group, a hydroxyl group or a lower C1-C6alkoxy group; R2 is a hydrogen atom or a lower C1-C6alkyl group; R3 is a hydrogen atom or a lower C1-C6alkyl group; R4 and R5 can be identical or different and are a hydrogen atom or a lower C1-C6alkyl group; R6 is a hydrogen atom or a lower C1-C6alkyl group; R7 is a phenyl group or a heterocyclic group which relates to a residue formed by removing a hydrogen atom from a saturated monocyclic heterocyclic ring containing one heteroatom in the ring, selected from an oxygen atom and a sulphur atom; in cases where R7 is a phenyl group or a heterocyclic group which relates to a residue formed by removing a hydrogen atom from a saturated monocyclic heterocyclic ring containing one heteroatom in the ring, selected from an oxygen atom and a sulphur atom, that phenyl or heterocyclic group can contain, as substitute(s), one or two groups selected from a halogen atom, a lower C1-C6alkyl group, a hydroxyl group, a lower C1-C6alkoxy group and a nitro group; W is an oxygen atom or NR8; R8 is a hydrogen atom or a lower C1-C6alkyl group; X is an oxygen atom or a sulphur atom; Y is a lower C1-C6alkylene group; Z is an oxygen atom, a sulphur atom, NR9 or OCO; R9 is a hydrogen atom or a lower C1-C6alkyl group. The invention also relates to a pharmaceutical composition based on said compounds, having GR binding activity. |
 Naphthalene carboxamide derivatives as protein kinase and histone deacetylase inhibitors, methods for preparing and using them / 2497809Invention refers to naphthalene carboxamide derivatives of general formula I which possess the properties of protein kinase or histone deacetylase inhibitors. The compounds can find application for preparing a drug for treating inflammatory diseases, autoimmune diseases, oncological disease, diseases of the nervous system and neurodegenerative diseases, allergies, asthma, cardiovascular diseases and metabolic diseases or disease related to hormonal diseases. In general formula I: , Z represents CH or N; each of the groups R1, R2 and R3 represents hydrogen, halogen, alkyl, alkoxy or trifluoromethyl; R4 represents or X represents a benzene ring or a pyridine ring; R5 represents one or more substitutes specified in a group consisting of hydrogen, halogen, alkyl, alkoxy or trifluoromethyl. The invention also refers to a method for preparing the above compounds, a pharmaceutical preparation and using them. |
 Benzyl derivatives of glycosides and methods of their application / 2492175Invention also relates to pharmaceutical compositions. Compounds of the formula given below are used for treatment of diabetes mellitus of type 1 or type 2, hyperglycemia, diabetic complications, insulin-resistance, metabolic syndrome, hyperinsulinemia, hypertension, obesity, edema, dislipidemia, chronic heart failure, atherosclerosis or related diseases, and can be introduced simultaneously or successively with at least one additional therapeutic agent, selected from group consisting of anti-diabetes agent, agent, which reduces content of lipids/modulates lipids, agent for treatment of diabetic complications, anti-obesity agent, hypotensive agent, anti-hyperuricemia agent and agent for treatment of chronic heart failure, atherosclerosis or related diseases. |
|
Method of treating depressed cases in newborns with surgical pathology / 2491088 Invention refers to medicine, namely paediatric resuscitation, and may be used for treating depressed cases in newborns with a surgical pathology. That is ensured by intravenous administration of 20% neat human serum albumin 3-5 ml/kg (no more than 1 g/kg) a day for 10 minutes. Observing persistent arterial hypertension requires an additional intravenous infusion of normal saline 3 ml/kg for 15 minutes, while in the presence of recurrent persistent arterial hypertension, 6% hydroxyethyl starch 3 ml/kg for 30 minutes is administered intravenously. |
 Spirocompounds and pharmaceutical application thereof / 2490250Invention refers to new compounds of the following general formula [1a], wherein R1 represents (1) a hydrogen atom, (2) C1-C6alkyl group, (3) C2-C6alkenyl group, (4) C2-C6alkynyl group, (5) C1-C6alkoxygroup, (6) hydroxyC1-C6alkyl group, (7) C1-C6alkoxy(C1-C6)alkyl group, (8) -CONR11R12, wherein R11 and R12 are identical or different, and each represents a hydrogen atom or C1-C6alkyl group, (9) phenyl group or (10) a five-member heteroaryl group which contains at least one heteroatom specified in a group consisting of a nitrogen atom and oxygen atom, and which may be substituted by C1-C6alkyl group; R2 represents (1) a halogen atom, (2) C1-C6alkyl group, (3) hydroxy group or (4) C1-C6alkoxy group; p is equal to 0, 1, 2 or 3; X represents a carbon atom or nitrogen atom; m1 is equal to 0, 1 or 2; m2 is equal to 0 or 1; the spiro ring AB may be substituted by 1-5 identical or different, specified in a group consisting of (1) hydroxy group, (2) C1-C6alkyl group, (3) C1-C6alkoxygroup and (4) oxo group; n1 is equal to 0, 1, 2, 3 or 4; n2 is equal to 1, 2, 3 or 4; n3 is equal to 0, 1 or 2, provided n2+n3 is equal to 2, 3 or 4; and a bond presented by the symbol means a single bond or a double bond, provided the three adjoining carbon atoms forms no allene bond presented by formula: C=C=C, or a pharmaceutically acceptable salt thereof. |
 Agent for cell metabolic process regulation / 2487720Invention refers to medicine, namely to using the preparation Infliximab as an agent regulating erythrocytes metabolism in the patients with inflammatory intestinal diseases. |
 Benzothiazole cyclobutyl amine derivatives as ligands of histamine h3-receptors, pharmaceutical composition based thereon, method for selective modulation of effects of histamine h3-receptors and method of treating condition or disorder modulated by histamine h3-receptors / 2487130Invention relates to compounds of formula (I), stereoisomers, trans- and cis-isomers, racemates or pharmaceutically acceptable salts thereof, having modulating activity on histamine H3-receptors. In formula (I) m equals 0; one of R1 and R2 is selected from a group which includes hydrogen, C1-10alkoxycarbonyl, amido-, carboxy-, C3-8cycloalkyl, halogen, -NRARB, (NRARB)carbonyl, or a group of formula -L2-R6; the other of R1 and R2 is selected from a group which includes hydrogen, halogen; each of R3a and R3b is independently selected from a group which includes hydrogen; each of R4 and R5 is independently selected from a group which includes C1-10alkyl and C1-10hydroxyalkyl; or R4 and R5, taken together with a nitrogen atom to which each is bonded, form a heteroaromatic ring of the type (a) or (b), where Q1 is O or C; Q2 is -N(R20)-; R20 is selected from a group which includes hydrogen and C1-10alkoxycarbonyl; each of p1 and p2 is independently equal to 1, 2 or 3; each of q1, q2, q3, q4 and q5 are independently equal to 0, 1 or 2; and wherein each carbon atom in the ring is substituted with hydrogen or 0, 1 or 2 substitutes, independently selected from a group which includes hydrogen, hydroxy group, fluorine, C1-10alkyl, C1-10hydroxyalkyl and C1-10fluoroalkyl; R6 is a phenyl, heterocycle or heterocycloC1-4alkyl, wherein the heterocycle is a 4-6-member aromatic or non-aromatic ring which contains 1 or 2 heteroatoms independently selected from N, O and S, optionally condensed with a benzene ring, wherein the phenyl or heterocycle can be unsubstituted or optionally substituted with one or more substitutes independently selected from a group which includes C1-4alkoxy, C1-4alkyl, cyano, halogen and oxo-; L is a bond or C1-4alkylene; L2 is a bond, C1-4alkylene, -C(=O)-, -SO2N(R14a)-, -N(R14a)SO2-, -C(O)N(R14a)-, -N(Rl4a)C(O)- or -N(R15)-; R10 is selected from a group which includes hydrogen; R14a is selected from a group which includes hydrogen; R15 is selected from a group which includes hydrogen; and RA and RB are independently selected from a group which includes hydrogen, C1-10alkyl, C1-10acyl, C1-4halogenalkyl, C1-10alkoxycarbonyl, C3-8cycloalkyl and C3-8cycloalkylcarbonyl. The invention also relates to a pharmaceutical composition which contains compounds of formula (I), a method for selective modulation of effects of histamine H3-receptors, use of said compounds in producing a medicament for treating a condition or disorder modulated by histamine H3-receptors, as well as specific compounds of formula (I). |
 Method for preparing water-soluble fractions of mannoproteins and β-glucan / 2504384Invention refers to pharmaceutical industry, namely to a method for preparing water-soluble fractions of mannoproteins and β-glucan. A method for preparing the water-soluble fractions of mannoproteins and β-glucan consisting in the fact that yeast biomass is prepared by mechanical activation in activators and mills; the prepared mechanical complex is added with a solution of enzymic complex showing β-glucanase or protease activity; that is followed by hydrolysis; the prepared hydrolysate is divided into mannoprotein and β-glucan fractions to be subject to purification under certain conditions. |
FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to cardiology, and may be used for treating and preventing arterial hypertension with metabolic syndrome. That is ensured by adding the food ration with the functional foodstuff 'Samarskiy Zdorovyak' No 61 in a min daily dose of 33.3 g per one intake - with breakfast or lunch or dinner with underlying drug-induced therapy.
EFFECT: enabled treatment and prevention of arterial hypertension with metabolic syndrome
The invention relates to medicine, in particular to cardiology, and for the treatment and prevention of arterial hypertension with metabolic syndrome.
There is a method of treatment of arterial hypertension dosed physical activity at further introduction of sudorific plant collection (RF patent №2303431, the priority date of 15.06.2005). Enables effective pressure reduction through sweating, accompanied by the release of chloride.
There is a method of treatment of arterial hypertension (patent 2418592, the priority date of 19.04.2010). According to the mode in the sequence specified in the complex conventional therapy impose additional prostaglandin E2 in the form of 0,0008% solution. Prostaglandin injected from a speed of 50 to 100 ng/kg/min, increasing the speed of every 10 minutes to 20-40 ng/kg/min, leading up to 150-300 ng/kg/min, for 40-60 minutes. Only three of the introduction to the course with intervals between them 1-2 days. The additional introduction of prostaglandin E2 in developed doses and mode provides effective normalization of blood pressure over the long term by strengthening the excretion of prostaglandins kidneys, expressed vasodilation of blood vessels of the kidney, heart and brain, as well as the normalization of the functional activity of platelets.
However, the treatment efficiency of these methods is insufficient. The methods of treatment do not provide influence on the basic links of the pathogenesis of the metabolic syndrome: overweight, hyperlipidemia, optimization of neurogenic regulation of vascular tone, reduction of daily index blood pressure.
The present invention is directed to achievement of the technical result, consisting in the increase of efficiency of treatment of patients with arterial hypertension with metabolic syndrome, due to the influence on the basic links of the pathogenesis of the metabolic syndrome: overweight, hyperlipidemia, reduction of daily index blood pressure.
This technical result is achieved by the fact that in the known method of treatment of arterial hypertension with metabolic syndrome (RF patent 2418592) additionally injected into the daily diet of functional food product (FRR) in a daily dose of no more than 100 g in equal doses, not less than 33.3 g in single-dose three times a day: Breakfast, lunch and dinner.
The method is as follows. In a bowl with a capacity of 250 ml fall asleep 3 tablespoons (not less than 33.3 d) dry product (powder in the form of dry cereal) and add to taste sugar or honey. Bred to desired consistency fluid with a temperature above 60 C (hot milk, water, milk products, juices, etc), mix thoroughly and cover. After a moment the product is ready to use. The specified product type to the basic ration of food three times a day - Breakfast, lunch and dinner. At the same time spend drug therapy.
Used functional food product is a product of a special purpose of natural origin, which is designed for systematic use and aims to fill the lack of energy in the body, plastic or regulatory food substances. By regulating effect on physical function, biochemical reactions and psychosocial human behavior, these products support the physical and spiritual health and reduce the risk of diseases.
For approbation of the method used FRR «Samara husky» (Russian Federation patents 2403802, 2403805, 2405380). The composition of the FRR «Samara big boy» provides antioxidant activity, through an adequate selenium + zinc + Vit. group+With+ folic acid. 100 g of the product FRR «Samara big boy» contains: two times greater (800 mcg) daily folic acid intake (in the norm of 400 mcg); iron - 26,26 mg (18 mg, selenium 50 mg (55 mg), zinc 6.3 mg (12.0 mg); magnesium 140,6 mg (400,0 mg); phosphorus 490,0 mg (800,0 mg) and others, as well as 20.8 g fiber (20,0 g).
Therapeutic and prophylactic nutrition therapy functional food product is a method of suppressing free radical activity, invasive detoxification of the human body, optimization of neurogenic regulation of vascular tone when the arterial hypertension (AH).
The constant use of FRR of the Samara big boy» with high content of antioxidants, vitamins and minerals, especially zinc and selenium, is a reliable tool in the treatment and prevention of hypertension.
During 2009 in the Federal state institution «Russian scientific centre of rehabilitation medicine and balneology Institute were carried out clinical trials on the topic «Evaluation of the effectiveness of dietary, medical and preventive food on the basis of the patent of Russian Federation №2403802, studying his , pre-biotic, hepatoprotective action on the metabolism of patients, as well as the study of neurogenic regulation of circulation and blood pressure in patients», fully confirmed the achievement of the technical result.
Under the supervision was 41 patients with arterial hypertension with the presence of metabolic syndrome I-III stage I-3 degree increase the level of blood pressure mainly high and very high risk of cardiovascular complications (according to who classification and GFCF, 2009). Of these, 85% were women, 15% - men, the average age of patients 56,8±3,95 years. Disease duration from 3 to 18 years. Patients given not more than 100 g FRR, in equal doses, three times a day, for Breakfast, lunch and dinner.
A random sample of all the patients were divided into two groups. I group (31 sick) took a functional food product «Samara big №61» 3 times a day for 3 weeks on a background of physiotherapeutic treatment (therapy) and medical gymnastics. II group (group of comparison, 10 patients) received only physiotherapy and therapeutic gymnastics. All patients received basic medical therapy.
In addition to common clinical examination carried out special methods of the research: was determined body mass index (BMI), waist circumference was measured; lipid metabolism were evaluated according to the level of cholesterol, triglycerides, cholesterol high-density lipoprotein (LDL HDL)cholesterol, low-density lipoprotein cholesterol (LDL); set glucose tolerance; evaluation of the daily schedule of blood was performed by the daily monitoring of arterial pressure. Check blood pressure was carried out with 15 min interval from 7 to 23 h 30 min from 23 to 7 PM
Results of observations (-P<0,01; -P<0.05). All the studied patients overweight (mean body mass index was 31.2 ħ 0,62 kg/sq.m (obesity of I-II level)), and manifestations of abdominal obesity (waist circumference is equal to 105.5±1,29). 57% of the patients had obesity of the first degree, 43% of patients had II degree obesity. 85% of violations of lipid spectrum, which were presented to the increase in total cholesterol in 85% of patients up to 5.85±of 0.08 mmol/l; reduction of 60% of patients HDL cholesterol and 0.92±of 0.04 mmol/l, increasing the level of LDL cholesterol to 3.9±0.06 mmol/l, increasing the level of triglycerides in the blood 47% of patients to 2.22 approximately 0.5 mmol/L.
All patients had hypertension. Hypertension (GB) stage II took place in 54% of patients with stage III - 46% of patients; 1 degree AG fixed - 15% of patients, 2 degree - 62%, grade 3 - in 23% of patients. Average risk was noted in 8% of patients with a high risk of 46% and very high - 46% of patients. Among concomitant diseases in 30% of patients recorded CHD, exertional angina of II FK, 38% of the patients Б, 8% of type 2 diabetes.
One-time clinical blood pressure in the outcome was increased: systolic blood pressure (SBP) in 92% of patients to 163, 64±2,99 (healthy - 126,11±4.2 mm Hg, p<0.01) and diastolic blood pressure (DBP) of 82% - up to 93.3±1,19, mm Hg(healthy 82,72±1,77 mm Hg, p<0.01).
In Exodus 50% of patients were highly increased heart rate (HR) to 89.0±0,55 UD/minutes (healthy 69,0 ħ 2.1 beats/min P<0.01), indicating an increase in the activity of the sympathoadrenal system.
As a result of treatment, both groups showed positive dynamics. However, in the group of patients having taken a functional food product «Samara husky, these changes were more pronounced: body mass index (BMI) in this group decreased from 31.5±0.62 to 27,44±of 0.26 (p<0.01). Waist circumference decreased by 1 basic group - with 105,0±1,41 to 101,7±1,42 2.3 see Blood glucose was not significantly changed. In the 2nd group dynamics was less pronounced.
In group 1 significantly decreased total cholesterol, triglycerides, while in group 2 showed only a tendency to reduce these indicators.
Positive dynamics of the clinical picture of the disease both groups of patients was confirmed by the dynamics of indicators of blood pressure, as according to one-time measurements, and daily monitoring of arterial pressure.
When analyzing the dynamics of arterial pressure according to the data of single measurements marked a distinct gipotenzivny effect with the achievement of the target blood pressure levels. In group I patients meals a day systolic blood pressure (SBP) decreased by 21%, diastolic blood pressure (DBP) decreased by 27%, in group 2, the pattern was less pronounced, respectively 18% and 21%.
According to the Smad a decline of average daily GARDEN, as well as average values GARDEN for the day and night in both groups, but in the main group hypotensive effect was higher was statistically significant reduction of time of hypertension GARDEN in the day time, night time period decreased hypertension GARDEN, indicating a decrease in the severity of the major risk factors for development of cardiovascular complications.
The increase in the index of time hypertension, reflecting the duration of the increase in blood pressure throughout the day, is an important risk factor for development of cardiovascular complications. Reduction of daily index, blood pressure, violation of circadian rhythm indicates a breach of neuro-humoral regulation of blood pressure.
Thus, the inclusion in the medical complex of functional food products based on FRR «Samara husky» (Russian Federation patent №2403802) contributes to a more marked reduction in the weight, BMI and reduction of waist circumference. Weight reduction is associated with a low calorie whole grain cereals that contain a lot of fiber and nutrients. Weight loss occurs very physiological, and when this body receives a large number of useful biologically active substances. Reducing the body weight and contributed to some greater hypotension effect, mainly in respect of the GARDEN.
The positive impact of the FRR on lipid manifested decrease in total cholesterol, LDL cholesterol and increase HDL cholesterol. This is connected with the position of lipid distress-syndrome, with increasing , restoration of motor-evacuation function of the gallbladder, a decrease of neurogenic tone of the sphincter of Oddi, that provides higher flow of bile into the intestine and creates all the metabolic conditions for the normalization of the mechanism of enterohepatic circulation of bile acids and digestive system. Improving the function of the liver, silymarin (contained in ) ingibiruet synthesis of cholesterol by reducing the activity of microsomal -COA reductase inhibitors, beta-glucan (contained in oat) improves the level of dezoksiholeva acid in the liver that helps to reduce the output from the liver cholesterol and prevent its reabsorption, normalizes the intestine for timely evacuation of bile acids, prevents constipation.
Thus, therapeutic effect of the FRR is implemented through function of the liver, by lowering hyperlipidemia, stimulation of lipolysis, increasing the antioxidant function, decrease of abdominal obesity, normalization of blood pressure. The obtained data allow to consider the application of the FRR as an adequate medicamentous method of increase of efficiency of treatment of patients with arterial hypertension with metabolic syndrome, which provides influence on the basic links of the pathogenesis of the metabolic syndrome: overweight, hyperlipidemia, arterial hypertension.
Results of clinical approbation of a functional food product «Samara big boy» with showed the effectiveness of the inclusion of the specified product in the diet of patients with diseases of cardio.
Therapeutic and preventive effect of the application of functional food product «Samara big boy» is confirmed in the report on the results of the clinical evaluation of the effectiveness of dietary Samara big guy» in the treatment and prevention of gastroenterological patients and cardiac profile approved by the Director of the FGI Russian research center of rehabilitation medicine and balneology of Ministry of health and social development of the RF, academician of the RAMP, Professor A.N. Razumov., 22.03.2010.
The additional introduction of FRR of the Samara big guy» in developed doses and mode provides effective normalization of blood pressure and metabolic disorders in the human body for a long period due to the liver function, by lowering hyperlipidemia, stimulation of lipolysis, increasing the antioxidant function, decrease of abdominal obesity, increase resistance to stress, as well as the normalization of the functional system operation regulation of the arteries. Application of functional food «Samara big boy» allows to control the number of free radicals, detoxifying and tissues, the preservation of elasticity of blood vessels of all sizes, improve blood circulation and microcirculation, normalization of neurogenic mechanisms of regulation of blood flow and blood pressure.
The method of treatment of arterial hypertension with metabolic syndrome, characterized in that in the background of medical additionally administered in the diet of functional food product «Samara husky # 61 of at least 33 g per reception - Breakfast, or lunch, or dinner.